Accelerate going overseas! Hengrui Pharma oral GLP-1/GIP obesity drug licensing deal with Novo has potential transaction value up to US$2.6 billion
An exclusive licensing deal expands future supply and distribution rights for an obesity drug candidate between Hengrui Pharma and Novo Nordisk.
Source →The trace
How it reaches your house.
Starting from GLP-1 drugs (Ozempic, Wegovy, Mounjaro), we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
GLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type) →Stands to benefitHengrui Pharma600276.SH
Hengrui is the licensor and stands to receive upfront, milestone and royalty payments from the deal, making it a direct beneficiary.
“Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties.”
98% confidenceCited →GLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type) →Stands to benefitNovo NordiskNVO
Novo Nordisk is the named licensee and gains exclusive global rights to develop, manufacture and commercialize HRS-1596, so it benefits materially from the expanded commercial opportunity.
92% confidence